Saturday 17 October 2026
Export AEON’s income statement to Excel — free account
AEON Biopharma, Inc.
AEON Healthcare Biotechnology
In the quarter to June 2026, EPS grew 96.7%, free cash flow fell 76.9% and total debt fell 88.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.23
0.01
−4.17%
Follow AEON
| Dec '17 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|
Current Ratio |
— | 0.31 | 1.00 | 0.12 | 0.48 | 0.11 | 0.49 |
Net Debt/EBITDA |
— | (5.53) | 0.26 | (2.51) | 0.01 | 0.16 | (2.48) |
Debt/Assets |
0.00% | 47.65% | 0.00% | 1,218.15% | 0.00% | 372.02% | 622.30% |
Debt/Equity |
— | 1.80 | 0.00 | (0.49) | 0.00 | (0.41) | (0.63) |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | 0.00 | (0.18) | 0.68 | 0.12 | (0.48) | 0.44 |
Capex/Depreciation |
— | — | — | (4.50) | 0.00 | 0.00 | (0.05) |
| — | 0.00% | (97.00%) | 36.58% | 181.66% | (46.26%) | 93.84% | |
| — | (8.89%) | 5.92% | (36.53%) | (4,365.11%) | 841.19% | (901.45%) | |
ROIC |
— | (5.45%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
— | 8.80% | 1,366,800.00% | 72.69% | 5,921.97% | (340.84%) | 1,175.37% |
Research and Development Expense of Revenue |
— | — | — | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | — | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
— | 0.00 | (15.80) | (18.60) | (92.68) | (37.58) | (1.74) |
Cash per Share |
— | 0.22 | 5.26 | 5.05 | 10.00 | 0.02 | 0.30 |
Shareholders Equity per Share |
— | 0.26 | (178.96) | (140.11) | (296.60) | (52.91) | (5.55) |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 0.26 | (178.96) | (140.11) | (296.60) | (52.91) | (5.55) |
Free Cash Flow |
— | — | (1.49) | (35.89) | (47.82) | (20.29) | (17.31) |
Working Capital |
— | (0.04) | 0.00 | (72.74) | (6.83) | (12.56) | (3.50) |
Capital Expenditures |
— | — | — | (0.31) | — | — | 0.00 |
Net Current Asset Value |
— | (0.04) | (293.04) | (271.35) | (153.67) | (30.12) | (57.19) |
| Other line items | |||||||
Quick Ratio |
— | 0.31 | 0.60 | 0.12 | 0.40 | 0.00 | 0.44 |
Depreciation/Fixed assets |
— | — | — | 0.16 | 0.30 | 0.41 | 0.48 |
Cash ROIC |
— | 0.00% | 9.10% | 27.74% | 32.34% | 120.31% | 99.37% |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
— | 0.00 | (15.80) | (18.44) | (92.68) | (37.58) | (1.74) |
Capex per Share |
— | 0.00 | 0.00 | (0.16) | 0.00 | 0.00 | 0.00 |
Average Payables |
— | 0.33 | 0.33 | 4.22 | 5.60 | 4.65 | 3.43 |
Average Assets |
— | 0.04 | 138.52 | 143.86 | 8.81 | 4.99 | 4.35 |
Average Common Equity |
— | 129.55 | (8.45) | (143.67) | (211.73) | (90.81) | (41.80) |
Capex to Sales |
— | — | — | 0.00 | — | — | 0.00 |
Columns are period end dates